Holen Sie sich die Stockscreener-App
348.73
1.09%
3.76
Handel nachbörslich:
348.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$344.97
Offen:
$343
24-Stunden-Volumen:
361.95K
Relative Volume:
1.07
Marktkapitalisierung:
$7.74B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-13.88
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+10.83%
1M Leistung:
+24.72%
6M Leistung:
+18.76%
1J Leistung:
+29.45%
1-Tages-Spanne:
$343.00
$352.00
1-Wochen-Bereich:
$307.43
$357.91
52-Wochen-Spanne:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
348.73 | 6.99B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - Yahoo Finance
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MyChesCo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover - AInvest
Madrigal Pharmaceuticals: Strong Surge or Overpriced? - StocksToTrade
Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news - Investing.com Canada
Madrigal’s Surge: Breakthrough in Liver Treatment? - timothysykes.com
Madrigal Pharmaceuticals Soars: Is It Time to Buy? - StocksToTrade
Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval - GuruFocus
Madrigal gains after Rezdiffra patent win (MDGL:NASDAQ) - Seeking Alpha
Madrigal stock jumps as patent protection for MASH treatment extended By Investing.com - Investing.com Nigeria
Madrigal stock jumps as patent protection for MASH treatment extended - Investing.com
Madrigal receives patent allowance for MASH treatment Rezdiffra By Investing.com - Investing.com India
Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use - GuruFocus
Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044 - Quiver Quantitative
Madrigal Pharmaceuticals Receives Notice of Allowance from - GlobeNewswire
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) - Yahoo Finance
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit - 富途牛牛
Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term - simplywall.st
MDGL Makes Notable Cross Below Critical Moving Average - Nasdaq
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s strong launch propels stock outlook - Investing.com
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Competito - GuruFocus
Altimmune’s phase IIb in MASH hits and misses, stock halves - BioWorld MedTech
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra - Yahoo Finance
Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperform (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals Receives Positive CHMP Opinion for Resmetirom in Treating MASH - MyChesCo
Resmetirom's EU Approval Milestone Positions Madrigal as NASH Market Leader - AInvest
Resmetirom's EU Nod Positions Madrigal as Pioneer in a $3 Billion MASH Market - AInvest
Madrigal Pharmaceuticals Awards Equity Grants to New Employees Under 2023 Inducement Plan - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals: Aligning Equity Incentives with Long-Term Value Creation - AInvest
EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com
(MDGL) Investment Analysis - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Madrigal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for MDGL - Nasdaq
Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(MDGL) On The My Stocks Page - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK
Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):